1.49
0.68%
+0.01
After Hours:
1.47
-0.02
-1.34%
Unity Biotechnology Inc stock is currently priced at $1.49, with a 24-hour trading volume of 36,549.
It has seen a +0.68% increased in the last 24 hours and a -5.10% declined in the past month.
The chart indicates a potential bullish trend, as the stock is below the $1.49 pivot point. If it approaches the $1.46 support level, significant changes may occur.
Unity Biotechnology Inc Stock (UBX) Financials Data
Unity Biotechnology Inc (UBX) Net Income 2024
UBX net income (TTM) was -$52.53 million for the quarter ending September 30, 2023, a +6.95% increase year-over-year.
Unity Biotechnology Inc (UBX) Cash Flow 2024
UBX recorded a free cash flow (TTM) of -$39.93 million for the quarter ending September 30, 2023, a +12.74% increase year-over-year.
Unity Biotechnology Inc (UBX) Earnings per Share 2024
UBX earnings per share (TTM) was -$3.66 for the quarter ending September 30, 2023, a +53.44% growth year-over-year.
Unity Biotechnology Inc Stock (UBX) Latest News
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
GlobeNewswire Inc.
Unity Biotechnology Upgraded - Analyst Highlights Cash Strength & Execution
Benzinga
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
GlobeNewswire Inc.
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Cap:
|
Volume (24h):